Update Potential Combination of Poolbeg & HOOKIPA

Holding(s) in Company

Update Potential Combination of Poolbeg & HOOKIPA

Combination of Poolbeg and HOOKIPA Pharma Inc.

POLB 001 Patent Granted in United States

Interim results for the six months to 30 June 2024

Holding(s) in Company

Voluntary Delisting from OTCQB Market

Notification of Major Holdings

Change of Registered Address

Result of AGM

Annual Report & AGM Notice

Significant POLB 001 Patent Granted in USA

Appointment of Joint Broker

Option Agreement to Acquire Orphan Drug Candidate

Results for the year ended 31 December 2023

TR-1: Notification of major holdings

Director/PDMR Shareholding

Director Share Purchase

Board Role Change and Launch of EIP

Further data shows POLB001 potential in cancer CRS

RSV AI Drug Candidate Analysis Update

POLB 001 Data Presented at ASH

Directorate Change

POLB001 Data to be Presented at ASH Annual Meeting

POLB 001 Oncology Programme Update Meeting

Poolbeg Partners with a Nasdaq-Listed Biopharma

Favourable Conclusion of Patent Opposition

Immunomodulator I Patent Opposition Withdrawal

Interim results for the six months to 30 June 2023

AI led programme identifies influenza drug targets

Oral Vaccine Programme Moves Forward

Board Appointment

Results of Annual General Meeting